APOE and neurodegenerative disease: Our results demonstrate that SAM is a particularly strong non-biological predictive index of cognitive decline in a preclinical population, compared to other markers such as SMC or AI that are commonly used with patients with neurodegenerative disease, and it is particularly predictive of decline for APOE ε4 carriers.